title: Phase II trial of amonafide in central nervous system tumors: a Southwest Oncology Group study.
abstract: Amonafide 300 mg/M2 was administered intravenously on a daily x 5 schedule to 27 eligible patients with recurrent or progressive central nervous system tumors. There were no objective responses. The most common toxicities were gastrointestinal, hematologic and neurologic. Further study of amonafide in patients with central nervous system malignancies is not indicated.
authors: University of Kansas Medical Center, Kansas City, USA.
authors: Sarah A
authors: SA
authors: Taylor
authors: Cathryn
authors: C
authors: Rankin
authors: Jeannette J
authors: JJ
authors: Townsend
authors: Johnny B
authors: JB
authors: Craig
authors: Ralph B
authors: RB
authors: Vance
authors: Dilip L
authors: DL
authors: Solank
authors: Thomas D
authors: TD
authors: Brown
authors: Kurt
authors: K
authors: Jaeckle
mesh_terms: D000225:Adenine; D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use* / Q000633:toxicity; D016543:Central Nervous System Neoplasms / Q000188:drug therapy*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007094:Imides / Q000008:administration & dosage / Q000627:therapeutic use* / Q000633:toxicity; D007262:Infusions, Intravenous; D007546:Isoquinolines / Q000008:administration & dosage / Q000627:therapeutic use* / Q000633:toxicity; D008297:Male; D053644:Naphthalimides; D063065:Organophosphonates
chemical_list: D000970:Antineoplastic Agents; D007094:Imides; D007546:Isoquinolines; D053644:Naphthalimides; D063065:Organophosphonates; C037020:amonafide; D000225:Adenine